Turtle Creek Wealth Advisors LLC Grows Stock Holdings in Stryker Corporation $SYK

Turtle Creek Wealth Advisors LLC grew its position in shares of Stryker Corporation (NYSE:SYK) by 11.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,107 shares of the medical technology company’s stock after purchasing an additional 2,731 shares during the period. Turtle Creek Wealth Advisors LLC’s holdings in Stryker were worth $8,579,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. DB Fitzpatrick & Co Inc lifted its position in Stryker by 22.1% in the 1st quarter. DB Fitzpatrick & Co Inc now owns 5,051 shares of the medical technology company’s stock worth $1,660,000 after buying an additional 915 shares during the last quarter. Private Advisor Group LLC grew its position in Stryker by 23.0% during the first quarter. Private Advisor Group LLC now owns 21,204 shares of the medical technology company’s stock valued at $6,967,000 after acquiring an additional 3,970 shares during the last quarter. Y Intercept Hong Kong Ltd grew its position in Stryker by 18.7% during the first quarter. Y Intercept Hong Kong Ltd now owns 34,580 shares of the medical technology company’s stock valued at $11,363,000 after acquiring an additional 5,445 shares during the last quarter. Leonteq Securities AG raised its stake in shares of Stryker by 348.3% during the first quarter. Leonteq Securities AG now owns 6,240 shares of the medical technology company’s stock worth $2,050,000 after acquiring an additional 4,848 shares in the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Stryker by 61.3% during the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 80,060 shares of the medical technology company’s stock worth $26,307,000 after acquiring an additional 30,437 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 4.2%

Shares of NYSE SYK opened at $326.41 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The firm’s fifty day moving average is $309.86 and its 200 day moving average is $338.96. The company has a market cap of $125.13 billion, a price-to-earnings ratio of 37.78, a PEG ratio of 2.01 and a beta of 0.77.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SYK shares. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Barclays decreased their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Canaccord Genuity Group cut their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Wells Fargo & Company reduced their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Finally, Evercore set a $355.00 target price on Stryker in a research note on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $395.33.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the transaction, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.